Form D · Other Health Care
Antigenix Therapeutics, Inc.
Princeton, NJ · CIK 0002073993
Offering snapshot reported Oct 24, 2025 · SEC filing
- Reported sold
- $3.36M Offering amount: $8.36M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 22, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 24, 2025 | Initial | $3,363,695 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-562071
Source: Form D, filed Oct 24, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kwesi Frimpong Boateng | Director |
| Shaun Hawkins | Director |
| Christopher Whitfield | Director, Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
300 Carnegie Center, Suite 150
Princeton, NJ, 08540
Princeton, NJ, 08540